Global Parkinson’s Disease Market Report: 2016 Edition - New Report by Koncept Analytics

1
Global Parkinsons Disease Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details

• Executive Summary
• Parkinsons Disease (PD) is a chronic and
  progressive neurodegenerative or movement
  disorder which involves the malfunction and death
  of vital nerve cells in the brain, called
  neurons. Parkinsons primarily affects neurons in
  an area of the brain called the substantia
  nigra. The early signs and symptoms may be mild
  and may go unnoticed initially. The cause of this
  disease is mainly unknown with no cure till date
  but there exist several treatment options such as
  medications and surgery.
• The current treatment market for Parkinsons
  disease has several unmet needs as no treatment
  has yet been successful in fully restoring the
  function that produces dopamine. However, the
  treatment currently only aims at controlling and
  relieving symptoms. The Parkinsons disease
  treatment market remains flooded by both branded
  and generic drugs. The market is expected to
  experience fluctuations in branded sales due to
  patent expiries and subsequent entry of generics
  in the market. Several biologics are under
  development for the treatment of Parkinsons
  along with possibility of developing Stem Cell
  as a treatment therapy.
• The Parkinsons disease market is expected to
  acquire modest growth driven by launch of new
  therapies and increasing rate of drug treatment
  due to increasing healthcare expenditure and
  ageing population. The major growth drivers of
  the Parkinsons disease market includes rising
  level of toxin exposure, increasing life
  expectancy, rising male population worldwide,
  ageing population, healthcare expenditure and
  pesticide consumption. However, the growth of the
  market will also remain challenged by generic
  erosion, current treatment limitations and
  increasing risk of developing Melanoma.
• The report, Global Parkinsons disease Market
  analyzes the currently prevailing condition of
  the market along with its future scope of
  development. The specific markets of the U.S.,
  the European Union and Japan are being discussed
  in the report. The major trends, growth drivers
  as well as issues being faced by the industry are
  being presented in this report. The major players
  in the industry are being profiled, along with
  their key financials and strategies for growth.

3
Growth of the Parkinsons disease drug market is
expected to be primarily driven by several
factors inclusive of increasing Parkinsons
disease prevalence, rise in ageing population
globally and increasing cost of treatment
therapies
Global Parkinsons Disease Drug Market by Value
(2010-2015E)

• The global Parkinsons disease drug market is
  estimated to have reached US... billion in the
  year 2015, increasing from US... billion in the
  previous fiscal year recording an annual growth
  of .
• The European Union accounted for the maximum
  share of in revenue of the global Parkinsons
  disease drug market for the year 2014. The U.S.
  accounted for second largest share of followed
  by Japan that held share.
• Both Dopamine agonists and COMT inhibitors are
  estimated to have held equal share of for the
  year 2015, followed by MAO inhibitors and
  Levodopa with expected share of and .
  respectively.

Global Parkinsons Disease Drug Market by Region
(2014)
Global Parkinsons Disease Market by Drug Class
(2015E)
4
The Parkinsons disease market in the U.S. has
high unmet needs in safety and efficacy, thus,
significantly suggesting that currently the
market is still served below par by the existing
treatment options
The U.S. Parkinsons Disease Market by Value
Volume (2013-2020E)

• The U.S. Parkinsons disease market reached
  US... million in the year 2015, with a further
  estimation of reaching US... million by the end
  of year 2020. In terms of prescription volume the
  market reached million in the year 2015.
• Both branded and generic drugs in the U.S. held
  equal share of of the overall revenue for the
  year 2015. The revenue share of generics will
  keep declining by the end of year 2017, recording
  an expected share of ...
• In 2015, majority of the Parkinsons patients in
  the U.S. were treated with MAO-Inhibitors with
  share of the total market followed by
  Levodopa/Carbidopa (gold standard) holding
  share.

The U.S. Parkinsons Disease Market Value by
Category (2013-2017E)
The U.S. Parkinsons Disease Market by Drug Class
(2015)
5
The Parkinsons Disease treatment market can
acquire modest growth in the coming years driven
by the launch of new therapies and increasing
drug treatment rates due to increasing healthcare
expenditure and ageing population
The U.S. Parkinsons Branded Drugs Market by
Volume/ Value (2013-2020E)

• The Parkinsons disease branded drugs market of
  the U.S. reached US.. million in 2015,
  increasing from US... million in the previous
  year recording an annual growth of . In terms
  of volume, the market reached million
  prescriptions decreasing from .. million in the
  previous fiscal year.
• The drug market for Parkinsons disease in the EU
  (Germany, France, the UK, Italy and Spain)
  reached US... million declining from US...
  million in the previous fiscal year.
• The Parkinsons disease market of Japan reached
  US... million in the year 2015, increasing from
  US... million in the previous fiscal year
  recording an annual growth of .

European Parkinsons Disease Drug Market by Value
(2014/2015)
Japans Parkinsons Disease Drug Market by Value
(2014/2015)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Parkinsons Disease Market . To know more about
this report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com